National Institute on Drug Abuse; Notice of Closed Meeting, 25098 [05-9508]

Download as PDF 25098 Federal Register / Vol. 70, No. 91 / Thursday, May 12, 2005 / Notices Agenda: To review procedures and discuss policies. Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852. Closed: June 23, 2005, 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852. Closed: June 24, 2005, 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Paul A. Rushing, PhD, Scientific Review Administrator, Review Branch, DEA, NIDDK, National Institutes of Health, Room 747, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8895, rushingp@extra.niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: May 6, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–9503 Filed 5–11–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Dental & Craniofacial Research; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 05–70, Review R21s (Genetics). Date: June 14, 2005. Time: 12 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892 (telephone conference call). VerDate jul<14>2003 19:04 May 11, 2005 Jkt 205001 Contact Person: H. George Hausch, PhD, Acting Director, 45 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892 (301) 594–2904, george_hausch@nih.gov. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 05–60, Review R25. Date: June 30, 2005. Time: 2 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892 (telephone conference call). Contact Person: Sooyoun (Sonia) Kim, MS, Associate SRA, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, National Inst. of Dental & Craniofacial Research, National Institute of Health, Bethesda, MD 20892, (301) 594–4827. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 05–58, Review R21s. Date: July 14, 2005. Time: 12 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892 (telephone conference call). Contact Person: Peter Zelazowski, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Activities, National Inst. of Dental & Craniofacial Research, National Institutes of Health, Bethesda, MD 20892–6402, (301) 593–4861. peter.zelazowski@nih.gov. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 05–66, Review of R21s (Perio/Micro). Date: July 18, 2005. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892 (telephone conference call). Contact Person: Yujing Liu, MD, PhD, Scientific Review Administrator, National Institute of Dental & Craniofacial Res., 45 Center Drive, Natcher Building, Rm. 4AN38E, Bethesda, MD 20892, (301) 594–3169, yujing_liu@nih.gov. Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 05–65, Review R21s (Oral Cancer). Date: July 19, 2005. Time: 10:30 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892, (telephone conference call). Contact Person: Peter Zelazowski, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Activities, National Inst. of Dental & Craniofacial Research, National Institutes of Health, Bethesda, MD 20892–6402, (301) 593–4861, peter.zelazowski@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 Disorders Research, National Institutes of Health, HHS) Dated: May 6, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–9504 Filed 5–11–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; SBIR II—‘‘Novel CBI Receptor Antagonists’’. Date: May 25, 2005. Time: 10 a.m. to 11 a.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call). Contact Person: Eric Zatman, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892– 8401. (301) 435–1438. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS) Dated: May 6, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–9508 Filed 5–11–05; 8:45 am] BILLING CODE 4140–01–M E:\FR\FM\12MYN1.SGM 12MYN1

Agencies

[Federal Register Volume 70, Number 91 (Thursday, May 12, 2005)]
[Notices]
[Page 25098]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-9508]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; SBIR II--``Novel CBI Receptor Antagonists''.
    Date: May 25, 2005.
    Time: 10 a.m. to 11 a.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852. (Telephone Conference Call).
    Contact Person: Eric Zatman, Contract Review Specialist, Office 
of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401. (301) 435-1438.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse Research Programs, National Institutes of Health, 
HHS)

    Dated: May 6, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-9508 Filed 5-11-05; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.